| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000027501 |
| Receipt No. | R000031501 |
| Official scientific title of the study | Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty. |
| Date of disclosure of the study information | 2017/05/26 |
| Last modified on | 2017/05/26 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Efficacy of Alendronate for the Prevention of Bone Loss in Calcar Region Following Total Hip Arthroplasty.
|
|
| Title of the study (Brief title) | Alendronate for the Prevention of Bone Loss around Total Hip Arthroplasty. | |
| Region |
|
|
| Condition | ||
| Condition | Osteoarthritis of hip joint | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Bone mineral density loss around femoral implants, particularly in the proximal femur, is a common outcome after total hip arthroplasty. Previous studies reported the prevention of postsurgical decreases in bone mineral density with the use of osteoporosis drug therapy. This randomized study evaluates the efficacy of alendronate and alfacalcidol for preserving bone mineral density over long-term follow-up. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Periprosthetic bone mineral density measured by dual-energy X-ray(Postoperative 1-year, 2-year, 8 to 9-year) |
| Key secondary outcomes | Occurrence of aseptic loosening and periprsthetic fracture |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of alendronate(5mg/day) after total hip arthroplasty atleast 2 years. | |
| Interventions/Control_2 | Administration of alphacalcidolfollowing(0.001g/day) total hip arthroplasty atleast 2 years. | |
| Interventions/Control_3 | No medication after surgery at least 2 years.
|
|
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who underwent primary total hip arthroplasty for osteoarthritis at our institute | |||
| Key exclusion criteria | (a) a history of disorder(s) that might affect bone or mineral metabolism, (b) gastrointestinal disease, (c) renal dysfunction, (d) taking any agents for osteoporosis, (e) taking corticosteroids, and (f) perioperative fracture of femur that required additional fixation using plates and wires. | |||
| Target sample size | 90 | |||
| Research contact person | |
| Name of lead principal investigator | Yukizawa, Yohei |
| Organization | Yokohama City University |
| Division name | Orthopaedic Surgery |
| Address | 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Kanagawa Japan |
| TEL | 045-787-2600 |
| snowriverjp@yahoo.co.jp | |
| Public contact | |
| Name of contact person | Inaba, Yutaka |
| Organization | Yokohama City University |
| Division name | Orthopaedic Surgery |
| Address | 3-9 Fuku-ura, Kanazawa-ku, Yokohama, Kanagawa Japan |
| TEL | 045-787-2600 |
| Homepage URL | |
| yute0131@med.yokohama-cu.ac.jp | |
| Sponsor | |
| Institute | Yokohama City University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Yokohama City University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031501 |